Hepatitis B virus –associated liver failure in a patient with B-cell non-Hodgkin lymphoma after anti-cancer therapy including ibrutinib

Bruton ’s tyrosine kinase (BTK) plays a pivotal role in B-cell proliferation and survival of leukemic cells. Ibrutinib, a molecule targeting BTK, was approved by the U.S. Food and Drug Administration in 2013 for treatment of mantle cell lymphoma and has since been approved for treatment of several other hematologic malignancies, including chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia, and marginal zone lymphoma (MZL) (1). Recently, Ibrutinib plus venetoclax have been found to be effective as first line treatment for high risk and older patients with CLL (2).

Source: Clinical Lymphoma, Myeloma and Leukemia - December 23, 2019 Category: Hematology Authors: Alexandre E. Malek, Yago Nieto, Ariel D. Szvalb, Shaheer Siddiqui, Mehnaz A. Shafi, Jessica P. Hwang, Issam I. Raad, Harrys A. Torres Tags: Case Report Source Type: research